Literature DB >> 9751097

Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis.

M Brewster1, E J Lewis, K L Wilson, A K Greenham, K M Bottomley.   

Abstract

OBJECTIVE: To determine the efficacy of a selective inhibitor of collagenases in an animal model of osteoarthritis (OA).
METHODS: Ro 32-3555, an orally active collagenase selective inhibitor, was administered to STR/ORT mice. Microfocal x-ray-generated images of the hind limbs were visually scored for joint space narrowing, osteophyte formation, and calcification of tendons. Histologic sections of the knees were scored for cartilage changes including loss of surface matrix, fibrillation, and eburnation.
RESULTS: Significant inhibition of joint space narrowing and osteophyte formation was achieved in groups of animals treated with 10-50 mg/kg(-1) of Ro 32-3555. These effects were confirmed histologically in the same groups of animals: histologic analysis revealed that Ro 32-3555 protected cartilage from degradative changes.
CONCLUSION: Ro 32-3555, a collagenase selective inhibitor, inhibits both the cartilage and bone changes in this mouse model of OA, and thus shows great potential as a treatment of OA in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751097     DOI: 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  27 in total

Review 1.  Matrix metalloproteinase inhibitors in rheumatic diseases.

Authors:  D R Close
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Low-Dose and Short-Duration Matrix Metalloproteinase 9 Inhibition Does Not Affect Adhesion Formation during Murine Flexor Tendon Healing.

Authors:  Caitlin A Orner; Michael B Geary; Warren C Hammert; Regis J O'Keefe; Alayna E Loiselle
Journal:  Plast Reconstr Surg       Date:  2016-03       Impact factor: 4.730

3.  Esculetin inhibits cartilage resorption induced by interleukin 1alpha in combination with oncostatin M.

Authors:  S Elliott; A D Rowan; S Carrère; P Koshy; J B Catterall; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

Review 4.  Clinical potential of matrix metalloprotease inhibitors in cancer therapy.

Authors:  E I Heath; L B Grochow
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

5.  Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology.

Authors:  Alvaro A Ordonez; Supriya Pokkali; Julian Sanchez-Bautista; Mariah H Klunk; Michael E Urbanowski; André Kübler; William R Bishai; Paul T Elkington; Sanjay K Jain
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

Review 6.  Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.

Authors:  William H Robinson; Christin M Lepus; Qian Wang; Harini Raghu; Rong Mao; Tamsin M Lindstrom; Jeremy Sokolove
Journal:  Nat Rev Rheumatol       Date:  2016-08-19       Impact factor: 20.543

Review 7.  Matrix metalloproteinase inhibitors: applications in oncology.

Authors:  D Yip; A Ahmad; C S Karapetis; C A Hawkins; P G Harper
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

8.  Repetitive Aerosol Exposure Promotes Cavitary Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction.

Authors:  Michael E Urbanowski; Elizabeth A Ihms; Kristina Bigelow; André Kübler; Paul T Elkington; William R Bishai
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

9.  Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis.

Authors:  Fabian D Liechti; Denis Grandgirard; David Leppert; Stephen L Leib
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

10.  Inhibition of interleukin-1beta-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D2.

Authors:  Nadia Zayed; Hassan Afif; Nadir Chabane; Leandra Mfuna-Endam; Mohamed Benderdour; Johanne Martel-Pelletier; Jean-Pierre Pelletier; Rajender K Motiani; Mohamed Trebak; Nicolas Duval; Hassan Fahmi
Journal:  Arthritis Rheum       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.